Pacific Edge (NZE:PEB, ASX:PEB) reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.
Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.
The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.
Pacific Edge said this move is "on the basis of the irreparable harm" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。